OK432 (Picibanil) in the Treatment of Lymphatic Malformations

PHASE2CompletedINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

October 5, 2005

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Lymphatic Malformations
Interventions
DRUG

OK432

OK432 will be injected at dosage of 0.01 to 0.05 mg/mL 6-12 weeks apart up to 4 injections total.

Trial Locations (14)

13210

SUNY Health Science Center, Syracuse

20010

Children's National Medical Center, Washington D.C.

23507

Children's Hospital of the Kings Daughter, Norfolk

33701

All Children's Hospital, St. Petersburg

37232

Vanderbilt University Hospital, Nashville

49546

Spectrum Health-SHMG Ear, Nose, & Throat, Grand Rapids

52242

Richard Smith, MD, Iowa City

53226

Children's Hospital of Wisconsin, Milwaukee

53279

University of Wisconsin Hospital & Clinic, Madison

55404

Children's Hospitals & Clinics of Minnesota - Minneapolis, Minneapolis

77030

Children's ENT of Houston, Houston

80218

The Children's Hospital of Denver, Denver

92123

Rady Children's Hospital & Health Center San Diego, San Diego

97239

Oregon Health Sciences University, Portland

All Listed Sponsors
lead

Richard JH Smith

OTHER

NCT03427619 - OK432 (Picibanil) in the Treatment of Lymphatic Malformations | Biotech Hunter | Biotech Hunter